Dispelling myths about drug procurement policy

by Marcel van Valen, David Jamieson, Lisa Parvin et al.
The Lancet Global Health, Vol. 6, No. 6, e609–e610, June 2018

2 pp. 40.6 kB
https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(18)30190-6.pdf

Drug prices are controversial in all countries, and nowhere more so than in low-income and middle-income countries, where access to essential drugs is very price sensitive. The higher the price, the fewer the patients who can be treated, so therefore the aim is to maintain drug prices consistently low. However, it is unclear whether the lowest price for a drug will always be the best value, and it is an issue that many purchasers must consider. Will quality be compromised? Will the bidder offering the lowest price be able to deliver on time and in full? Unsatisfactory answers to these key questions will put lives at risk

(Visited 18 times, 1 visits today)
This entry was posted in Essential Medicines, General, Global Health. Bookmark the permalink.